Coherent Sine Burst Electroporation (CSE) Ablation System US IDE Study for Patients With Atrial Fibrillation

A trial with no phase registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 360 participants.

Also called NCT06784466

  • Study
  • In this atlas

Overview

Design
Interventional study; non-randomized; no masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 360 participants (planned count) (from the registry)
Sponsor
Arga Medtech SA (from the registry)
Registry
  • NCT NCT06784466
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States, Belgium, Croatia, Czechia, Lithuania, Netherlands (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT06784466. Non-randomized; no masking; primary purpose treatment. Start 2025-09-10 (actual); primary completion 2027-06 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Coherent Sine Burst Electroporation (CSE) Ablation System US IDE Study for Patients With Atrial Fibrillation
Acronym
COHERENT-AF
Condition
Atrial Fibrillation (AF)
Condition
Persistant Atrial Fibrillation
Condition
Paroxysmal AF
Intervention (Device)
Argá Medtech Coherent Sine-Burst Electroporation (CSE) Ablation System
Lead sponsor
Arga Medtech SA (class: industry)

Record details

Record id
cardio:ct-nct06784466
Content hash
b9cd2c32c58bd6b1f872b23b1cbb30f34877157d1ec7422f685d87b2dcbf7403